Drugs targeting receptors of the neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) are widely used in neuropsychiatry and some such agents, most notably psilocybin, have shown potential for further drug development, but hallucinogenic effects have limited their clinical use. The findings of a new multicenter Chinese structural pharmacology study may now provide a solid basis for the structure-based design of safe and nonhallucinogenic psychedelic analogues with therapeutic efficacy, the authors reported in the January 28, 2022, edition of Science.